Wednesday, May 29, 2024
Menten AI, Inc., a biotech company specializing in peptide macrocycle design and optimization through AI, has announced the completion of a collaborative research venture with Bristol Myers Squibb. This partnership, previously undisclosed, utilized Menten AI's advanced platform for enhancing cyclic peptide optimization.
Menten AI's platform integrates machine learning, physics-based models, and quantum chemistry simulations. Instead of sorting through vast molecule libraries, their generative AI technology navigates chemical space directly, simplifying the identification of macrocycles with desired properties. This approach reduces the need for wet lab testing and iteration cycles, speeding up the achievement of drug-like characteristics.
During this collaboration, Menten AI and Bristol Myers Squibb worked together to refine the biochemical properties of specific peptide macrocycles. They explored a broader chemical space, discovering novel amino acid modifications to enhance desired traits.
Menten AI, emphasized the significance of this achievement for the company, highlighting the maturity of their platform and the potential of generative AI in accelerating the discovery and optimization of next-generation peptide macrocycles.
Source: businesswire.com
